GlaxoSmithKline Capital PLC Publication of a Prospectus (1383V)

TIDMAG99

RNS Number : 1383V

GlaxoSmithKline Capital PLC

04 August 2020

Publication of Base Prospectus

The following base prospectus dated 4(th) August 2020 has been approved by the Financial Conduct Authority and is available for viewing:

GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GSK Capital K.K. GBP20,000,000,000 Euro Medium Term Note Programme

Copies of the base prospectus and the documents incorporated by reference within it have been submitted to the UK Listing Authority's NSM submission portal via the Electronic Submission System (ESS). The base prospectus w ill shortly be available for inspection at and can be downloaded from:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism .

For further information, please contact:

GlaxoSmithKline plc

980 Great West Road

Brentford

Middlesex

TW8 9GS

United Kingdom

Enquiries:

 
                              Mary Hinks-Edwards    [phone] 
                               David Mawdsley        [phone] 
 UK Media enquiries:           Simon Steel           [phone] 
 European Analyst/Investor    James Dodwell         [phone] 
  enquiries:                   Danielle Smith        [phone] 
 

BASIS ON WHICH YOU MAY ACCESS THE BASE PROSPECTUS

Please note that the information contained in the base prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the base prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the base prospectus is not addressed. Prior to relying on the information contained in the base prospectus you must ascertain from the base p rospectus whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirements.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

PDIBRGDICDGDGGS

(END) Dow Jones Newswires

August 04, 2020 13:30 ET (17:30 GMT)